Creo Medical Group (CREO.L) Stock Price
Creo Medical Group Price
Revenue has compounded at 20.1% per year over the past 11 years to 6.00 M GBP. Creo Medical Group's net margin stands at 88.3%, up from -97.8% several years earlier. Analysts set a median price target of 40.80 GBP, implying 35,692.6% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
Creo Medical Group stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Creo Medical Group business model & stock analysis
Frequently asked questions about Creo Medical Group
The business model of Creo Medical Group PLC revolves around developing and commercializing medical devices for surgical endoscopy. Creo Medical specializes in advanced energy devices and aims to provide innovative solutions for minimally invasive procedures, such as radiofrequency ablation and microwave coagulation. By leveraging its proprietary technology, Creo Medical aims to enable healthcare professionals to improve patient outcomes, minimize complications, and reduce healthcare costs. With a focus on enhancing clinical capabilities and expanding its product portfolio, Creo Medical Group PLC continues to drive innovation in the medical device industry.
Creo Medical Group PLC is primarily active in the medical technology industry.
The main competitors of Creo Medical Group PLC in the market are (insert competitor names here).
Creo Medical Group PLC, a leading medical device company based in the UK, was founded in 2003. The company specializes in the development and commercialization of advanced surgical instruments. Creo Medical has a strong focus on non-invasive surgical technologies that provide effective treatments with minimal patient discomfort and enhanced recovery. With a talented team of professionals, Creo Medical has achieved significant milestones in its history, including the successful launch of its flagship device, the CROMA™ Advanced Energy Platform. The company is committed to driving innovation in the medical field, working towards improving patient outcomes and revolutionizing surgical procedures globally. Creo Medical Group PLC continues to grow and establish a strong presence in the market through its dedication to research, development, and commercialization of cutting-edge medical devices.
Creo Medical Group PLC has achieved significant milestones since its establishment. Some noteworthy achievements include the FDA clearance for their Speedboat RS2 device, allowing the company to enter the US market and expand its customer base. Additionally, Creo Medical Group PLC received CE Mark approval for its CROMA platform, enabling commercialization in the European market. The company also secured key partnerships and collaborations with renowned medical institutions and professionals, highlighting its commitment to innovation and development in the medical device sector. With these milestones, Creo Medical Group PLC has established itself as a leading player in the field, dedicated to improving patient outcomes through advanced technology.
Creo Medical Group PLC is primarily present in various countries and regions around the world. Some of the key markets where the company operates include the United Kingdom, Europe, Asia-Pacific, and North America. With its global presence, Creo Medical Group PLC caters to a wide range of customers and investors across different geographical locations.
Creo Medical Group PLC represents values such as innovation, integrity, and excellence. The company is dedicated to delivering cutting-edge medical solutions to improve patient outcomes. Creo Medical Group PLC follows a patient-centric approach, ensuring that their products and technologies meet the highest standards of quality and effectiveness. Their corporate philosophy emphasizes the importance of collaboration, research, and development to provide advanced therapeutic solutions in the field of endoscopy and minimally invasive surgery. With a strong focus on continuous improvement and customer satisfaction, Creo Medical Group PLC strives to contribute to the advancement of medical technology for the benefit of patients worldwide.
Analysts currently set an average price target of 40.80 GBP for the Creo Medical Group stock (median: 40.80 GBP), implying +257.9 % versus the latest price. The consensus is based on 5 analyst ratings.
6 analysts currently rate the Creo Medical Group stock: 5 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Creo Medical Group to generate revenue of 9.10 M GBP and earnings per share of -0.02 GBP.
Converted at the current exchange rate, the Creo Medical Group share trades at 0.14 EUR (0.11 GBP).
Creo Medical Group PLC is a British medical technology company that specializes in the development and marketing of advanced medical technologies for endoscopy. The company was founded in 2003 and is headquartered in Chepstow, Wales.
The expected revenue of Creo Medical Group is 9.10 M GBP. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Creo Medical Group is -7.95 M GBP. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Creo Medical Group is currently -5.92. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Creo Medical Group stock.
The price-to-sales ratio (P/S) of Creo Medical Group is currently 5.17. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Creo Medical Group stock.
The Eulerpool Quality Score for Creo Medical Group is 4/10.
The ISIN of Creo Medical Group is GB00BZ1BLL44. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Creo Medical Group is A2DH40. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Creo Medical Group is CREO.L. The ticker symbol is used to trade Creo Medical Group shares on the stock exchange.
Creo Medical Group stock
Creo Medical Group Peer Group
Creo Medical Group FIGI
All fundamentals and in-depth analysis of Creo Medical Group
Our stock analysis for Creo Medical Group stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Creo Medical Group. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.